Cargando…
Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening
The primate-specific brain voltage-gated potassium channel isoform Kv11.1-3.1 has been identified as a novel therapeutic target for the treatment of schizophrenia. While this ether-a-go-go related K( + )channel has shown clinical relevance, drug discovery efforts have been hampered due to low and in...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754628/ https://www.ncbi.nlm.nih.gov/pubmed/26879421 http://dx.doi.org/10.1038/srep19976 |
_version_ | 1782416055539335168 |
---|---|
author | Calcaterra, Nicholas E. Hoeppner, Daniel J. Wei, Huijun Jaffe, Andrew E. Maher, Brady J. Barrow, James C. |
author_facet | Calcaterra, Nicholas E. Hoeppner, Daniel J. Wei, Huijun Jaffe, Andrew E. Maher, Brady J. Barrow, James C. |
author_sort | Calcaterra, Nicholas E. |
collection | PubMed |
description | The primate-specific brain voltage-gated potassium channel isoform Kv11.1-3.1 has been identified as a novel therapeutic target for the treatment of schizophrenia. While this ether-a-go-go related K( + )channel has shown clinical relevance, drug discovery efforts have been hampered due to low and inconsistent activity in cell-based assays. This poor activity is hypothesized to result from poor trafficking via the lack of an intact channel-stabilizing Per-Ant-Sim (PAS) domain. Here we characterize Kv11.1-3.1 cellular localization and show decreased channel expression and cell surface trafficking relative to the PAS-domain containing major isoform, Kv11.1-1A. Using small molecule inhibition of proteasome degradation, cellular expression and plasma membrane trafficking are rescued. These findings implicate the importance of the unfolded-protein response and endoplasmic reticulum associated degradation pathways in the expression and regulation of this schizophrenia risk factor. Utilizing this identified phenomenon, an electrophysiological and high throughput in-vitro fluorescent assay platform has been developed for drug discovery in order to explore a potentially new class of cognitive therapeutics. |
format | Online Article Text |
id | pubmed-4754628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47546282016-02-24 Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening Calcaterra, Nicholas E. Hoeppner, Daniel J. Wei, Huijun Jaffe, Andrew E. Maher, Brady J. Barrow, James C. Sci Rep Article The primate-specific brain voltage-gated potassium channel isoform Kv11.1-3.1 has been identified as a novel therapeutic target for the treatment of schizophrenia. While this ether-a-go-go related K( + )channel has shown clinical relevance, drug discovery efforts have been hampered due to low and inconsistent activity in cell-based assays. This poor activity is hypothesized to result from poor trafficking via the lack of an intact channel-stabilizing Per-Ant-Sim (PAS) domain. Here we characterize Kv11.1-3.1 cellular localization and show decreased channel expression and cell surface trafficking relative to the PAS-domain containing major isoform, Kv11.1-1A. Using small molecule inhibition of proteasome degradation, cellular expression and plasma membrane trafficking are rescued. These findings implicate the importance of the unfolded-protein response and endoplasmic reticulum associated degradation pathways in the expression and regulation of this schizophrenia risk factor. Utilizing this identified phenomenon, an electrophysiological and high throughput in-vitro fluorescent assay platform has been developed for drug discovery in order to explore a potentially new class of cognitive therapeutics. Nature Publishing Group 2016-02-16 /pmc/articles/PMC4754628/ /pubmed/26879421 http://dx.doi.org/10.1038/srep19976 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Calcaterra, Nicholas E. Hoeppner, Daniel J. Wei, Huijun Jaffe, Andrew E. Maher, Brady J. Barrow, James C. Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening |
title | Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening |
title_full | Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening |
title_fullStr | Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening |
title_full_unstemmed | Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening |
title_short | Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening |
title_sort | schizophrenia-associated herg channel kv11.1-3.1 exhibits a unique trafficking deficit that is rescued through proteasome inhibition for high throughput screening |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754628/ https://www.ncbi.nlm.nih.gov/pubmed/26879421 http://dx.doi.org/10.1038/srep19976 |
work_keys_str_mv | AT calcaterranicholase schizophreniaassociatedhergchannelkv11131exhibitsauniquetraffickingdeficitthatisrescuedthroughproteasomeinhibitionforhighthroughputscreening AT hoeppnerdanielj schizophreniaassociatedhergchannelkv11131exhibitsauniquetraffickingdeficitthatisrescuedthroughproteasomeinhibitionforhighthroughputscreening AT weihuijun schizophreniaassociatedhergchannelkv11131exhibitsauniquetraffickingdeficitthatisrescuedthroughproteasomeinhibitionforhighthroughputscreening AT jaffeandrewe schizophreniaassociatedhergchannelkv11131exhibitsauniquetraffickingdeficitthatisrescuedthroughproteasomeinhibitionforhighthroughputscreening AT maherbradyj schizophreniaassociatedhergchannelkv11131exhibitsauniquetraffickingdeficitthatisrescuedthroughproteasomeinhibitionforhighthroughputscreening AT barrowjamesc schizophreniaassociatedhergchannelkv11131exhibitsauniquetraffickingdeficitthatisrescuedthroughproteasomeinhibitionforhighthroughputscreening |